Professional development Vacancies

Ciprofloxacin (systemic use)

08.02.2019 Updated 26.11.2020 3298 views

Dear applicants!

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the assessment of the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing Ciprofloxacin, using post-marketing surveillance data and literature, recommended that registration certificate holders of medicinal products containing Ciprofloxacin amend the instructions for medical use by adding safety information regarding:

  • syndrome of inappropriate antidiuretic hormone secretion with frequency “unknown”;
  • cases of hypoglycemic coma.

List of medicinal products containing Ciprofloxacin and approved for medical use in Ukraine (according to the State Register of Medicinal Products as of 29.01.2019.

Linkhttps://www.ema.europa.eu/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product/00000775/201801_en.pdf